Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Meijers-Heijboer, C. Brekelmans, M. Menke-Pluymers, C. Seynaeve, A. Baalbergen, C. Burger, E. Crepin, A. Ouweland, B. Geel, J. Klijn (2003)Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 9
(2003)Use of genetic testing and prophylactic surgery in families with a BRCA 1 or BRCA 2 mutation
T. Rebbeck, H. Lynch, S. Neuhausen, S. Narod, L. Veer, J. Garber, G. Evans, C. Isaacs, M. Daly, E. Matloff, O. Olopade, B. Weber (2002)Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
The New England journal of medicine, 346 21
D. Easton, D. Ford, D. Bishop (1995)Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
American journal of human genetics, 56 1
(2002)Prophy - lactic oophorectomy in carriers of BRCA 1 or BRCA 2 mutations
ML Slattery, RA Kerber (1993)A comprehensive evaluation of family history and breast cancer risk
(2008)International variation of uptake of preventive options in BRCA 1 and BRCA 2 mutation carriers
N. Kauff, J. Satagopan, M. Robson, Lauren Scheuer, M. Hensley, C. Hudis, N. Ellis, J. Boyd, P. Borgen, R. Barakat, L. Norton, K. Offit (2002)Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
Obstetrical & Gynecological Survey, 57
J. Piek, B. Torrenga, B. Hermsen, R. Verheijen, R. Zweemer, J. Gille, P. Kenemans, P. Diest, F. Menko (2004)Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study
Familial Cancer, 2
(2003)Histopathological characteristics of BRCA 1 - and BRCA 2 - associated intraperitoneal cancer : a clinic based study
M. Callahan, C. Crum, F. Medeiros, D. Kindelberger, J. Elvin, J. Garber, C. Feltmate, R. Berkowitz, M. Muto (2007)Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 25
(2002)Prevention and Observation of Surgical End Points Study Group et
C. Powell, Eric Kenley, Lee-may Chen, B. Crawford, Jane McLennan, C. Zaloudek, M. Komaromy, M. Beattie, J. Ziegler (2005)Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 1
GA Colditz, WC Willett, DJ Hunter (1993)Family history, age and risk of breast cancer
G. Colditz, W. Willett, D. Hunter, M. Stampfer, J. Manson, C. Hennekens, Bernard Rosner, F. Speizer (1993)Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study.
JAMA, 270 3
(2009)BRCA trial. http://www.breakthroughresearch.org.uk/clinical_trials_ clinical_researchers/clinical_trials/brca_trial/index.html
M. Slattery, R. Kerber (1993)A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database.
JAMA, 270 13
B. Heemskerk-Gerritsen, C. Brekelmans, M. Menke-Pluymers, A. Geel, M. Tilanus-Linthorst, C. Bartels, M. Tan, H. Meijers-Heijboer, J. Klijn, C. Seynaeve (2007)Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
Annals of Surgical Oncology, 14
D. Thompson, D. Easton (2003)Cancer incidence in BRCA1 mutation carriers
A description of the first oncogenetic clinic for BRCA 1 / 2 mutation carriers in London : The Carrier Clinic
ND Kauff, JM Satagopan, ME Robson (2002)Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
N Engl J Med, 346
MS Brose, TR Rebbeck, KA Calzone (2002)Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program
J Natl Cancer Inst, 94
K. Metcalfe, D. Birenbaum-Carmeli, J. Lubiński, J. Gronwald, H. Lynch, P. Møller, P. Ghadirian, W. Foulkes, J. Klijn, E. Friedman, C. Kim-sing, P. Ainsworth, B. Rosen, S. Domchek, T. Wagner, N. Tung, S. Manoukian, F. Couch, P. Sun, S. Narod (2008)International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
International Journal of Cancer, 122
Adopted March (2003)American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
M. Brose, T. Rebbeck, K. Calzone, J. Stopfer, K. Nathanson, B. Weber (2002)Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
Journal of the National Cancer Institute, 94 18
DF Easton (1995)Breast and ovarian cancer incidence in BRCA1-mutation carriers
Am Hum Gen, 56
The purpose of this study is to measure the impact of a multidisciplinary one-stop follow-up clinic (MDOSC) on breast and ovarian surveillance, risk reducing surgery and enrolment in clinical trials in BRCA1/2 carriers. All BRCA1/2 carriers in our region were invited and chose which specialists to see in our MDOSC offering best practice using clinical protocols based on national guidelines and published data. Uptake was evaluated over 24 months recording numbers of individuals undergoing breast and ovarian surveillance, risk reducing surgery, newly diagnosed cancers, their method of detection and participation in clinical trials. 172 (60%) of invited BRCA1/2 carriers chose to attend the MDOSC. Breast surveillance was initiated in 88% and screening frequency altered in 14% of women to comply with national guidelines. Risk reducing salpingo-oophorectomy was chosen by 47% of women and an additional 39% were considering it. The rate of failure to remove fallopian tubes fell from 15 to 3% of procedures (P < 0.01) and peritoneal washings and serial sectioning of tubes and ovaries rose from 25% and 14% before, to 67% (P < 0.001) and 63% (P < 0.001) procedures, respectively, after initiation of our MDOSC. 24% of women considered and 18% decided to undergo risk reducing mastectomy during the follow-up period. Participation in clinical trials increased significantly from 51 to 229 enrolments (P < 0.001). Our novel MDOSC designed to devise an individually tailored cancer risk management strategy had a high uptake amongst our BRCA1/2 carriers. Attendance resulted in improved breast and ovarian cancer risk management.
Familial Cancer – Springer Journals
Published: Mar 19, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.